Heidi L Yoder

US Patent:

20090232795, Sep 17, 2009

Filed:

Feb 6, 2009

Appl. No.:

12/322861

Inventors:

Jon H. Condra - Doylestown PA, US
Rose M. Cubbon - Fanwood NJ, US
Holly A. Hammond - Telford PA, US
Timothy McCabe - Doylestown PA, US
Shilpa Pandit - Edison NJ, US
Laurence B. Peterson - Westfield NJ, US
Joseph C. Santoro - Belle Mead NJ, US
Ayesha Sitlani - Metuchen NJ, US
Dana D. Wood - Collegeville PA, US
Henryk Mach - Ambler PA, US
Heidi Yoder - Glenside PA, US
Sonia M. Gregory - Blue Bell PA, US
Jeffrey T. Blue - Telford PA, US
Kevin Wang - Lansdale PA, US
Peter Luo - Lansdale PA, US
Denise K. Nawrocki - Annandale NJ, US
Pingyu Zhong - Blue Bell PA, US
Feng Dong - Lansdale PA, US
Yan Li - San Jose CA, US

International Classification:

A61K 39/395
C07K 16/00
C07H 21/04
C12N 15/63
C12N 5/00
C12P 21/06

US Classification:

4241301, 5303871, 536 2353, 4353201, 435325, 435 691

Abstract:

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

US Patent:

20090246192, Oct 1, 2009

Filed:

Feb 6, 2009

Appl. No.:

12/322867

Inventors:

Jon H. Condra - Doylestown PA, US
Rose M. Cubbon - Fanwood NJ, US
Holly A. Hammond - Telford PA, US
Laura Orsatti - Pomezia, IT
Shilpa Pandit - Edison NJ, US
Laurence B. Peterson - Westfield NJ, US
Joseph C. Santoro - Belle Mead NJ, US
Ayesha Sitlani - Metuchen NJ, US
Dana D. Wood - Collegeville PA, US
Henryk Mach - Ambler PA, US
Heidi Yoder - Glenside PA, US
Sonia M. Gregory - Blue Bell PA, US
Jeffrey T. Blue - Telford PA, US
Kevin Wang - Lansdale PA, US
Peter Luo - Lansdale PA, US
Denise K. Nawrocki - Annandale NJ, US
Pingyu Zhong - Blue Bell PA, US
Feng Dong - Lansdale PA, US
Yan Li - San Jose CA, US

International Classification:

A61K 39/395
C07K 16/18
C07H 21/04
C12N 15/63
C12N 5/16
C12P 21/06

US Classification:

4241301, 5303871, 536 2353, 4353201, 435326, 435 696

Abstract:

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

US Patent:

20120301461, Nov 29, 2012

Filed:

May 8, 2012

Appl. No.:

13/466439

Inventors:

Jon H. Condra - Doylestown PA, US
Rose M. Cubbon - Fanwood NJ, US
Holly A. Hammond - Telford PA, US
Laura Orsatti - Ponezia, IT
Shilpa Pandit - Edison NJ, US
Laurence B. Peterson - Westfield NJ, US
Joseph C. Santoro - Belle Mead NJ, US
Ayesha Sitlani - Metuchen MA, US
Dana D. Wood - Collegeville PA, US
Henryk Mach - Amber PA, US
Heidi Yoder - Glenside PA, US
Sonia M. Gregory - Charlottesville VA, US
Jeffrey T. Blue - Telford PA, US
Kevin Wang - Lansdale PA, US
Peizhi (Peter) Luo - Lansdale PA, US
Denise K. Nawrocki - Annandale NJ, US
Pingyu Zhong - Blue Bell PA, US
Feng Dong - Lansdale PA, US
Yan Li - San Jose CA, US

International Classification:

C07K 16/40
C12N 15/13
C12N 1/21
A61P 9/00
C12N 7/01
C12N 5/10
C12P 21/00
A61K 39/395
C12N 1/19

US Classification:

4241331, 5303873, 5303891, 536 2353, 4353201, 43525233, 43525231, 43525235, 4352542, 4352351, 435325, 435 696

Abstract:

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

US Patent:

20130071379, Mar 21, 2013

Filed:

May 8, 2012

Appl. No.:

13/466433

Inventors:

Jon H. Condra - Doylestown PA, US
Rose M. Cubbon - Fanwood NJ, US
Holly A. Hammond - Telford PA, US
Timothy McCabe - Doylestown PA, US
Shilpa Pandit - Edison NJ, US
Laurence B. Peterson - Westfield NJ, US
Joseph C. Santoro - Belle Mead NJ, US
Ayesha Sitlani - Metuchen MA, US
Dana D. Wood - Collegeville PA, US
Henryk Mach - Amber PA, US
Heidi Yoder - Glenside PA, US
Sonia M. Gregory - Charlottesville VA, US
Jeffrey T. Blue - Telford PA, US
Kevin Wang - Lansdale PA, US
Peter Luo - Lansdale PA, US
Denise K. Nawrocki - Annandale NJ, US
Pingyu Zhong - Blue Bell PA, US
Feng Dong - Lansdale PA, US
Yan Li - San Jose CA, US

International Classification:

A61K 39/395
C07K 16/40
C07K 16/30
C12P 21/02
C12N 5/07

US Classification:

4241331, 5303873, 5303891, 4241581, 536 2353, 4353201, 435 696, 43525233, 435328, 435338

Abstract:

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.